First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults

INTRODUCTION: AOD01 is a novel, fully human immunoglobulin (Ig) G1 neutralizing monoclonal antibody that was developed as a therapeutic against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). This first-in-human study assessed safety, tolerability, pharmacokinetics (PK), and pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Prativadibhayankaram, Venkateshan S., Lee, Lawrence Soon-U, Lye, David, Xiaoying, Xu, Nellore, Ranjani, Pendharkar, Vishal, Hentze, Hannes, Guan, Siyu, Ayers, Benjamin J., Seah, Shirley G. K., Chye, De Hoe, Talib, Najwa S. N., Kaliaperumal, Nivashini, Ong, Wei Yee, Wong, Zi Xin, Au, Veonice B., Alok, Anshula, Connolly, John E., Boyd-Kirkup, Jerome D., Ingram, Piers J., Hanson, Brendon J., Ethirajulu, Kantharaj, O’Connell, Damian, Chan, Conrad E. Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441134/
https://www.ncbi.nlm.nih.gov/pubmed/36058990
http://dx.doi.org/10.1007/s40121-022-00681-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441134/
https://www.ncbi.nlm.nih.gov/pubmed/36058990
http://dx.doi.org/10.1007/s40121-022-00681-1

Ejemplares similares